BTK and neoplasm: Among the tested compounds, BTK inhibition with Acalabrutinib enhanced tumor cell depletion and reduced exhaustion marker expression in the core regions, consistent with previous observations, which improved CAR T‐cell expansion and reduced dysfunctional subsets, including exhausted T cells and regulatory T cells (Tregs).46, 48, 49, 50, 52, 58